Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer

By Mello-Grand Maurizia  

Breast Cancer Research and Treatment, Vol. 121, Iss. 2, 2010-06 ,pp. : 399-411

Springer Publishing Company

Access to resources Recommend Favorite

ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole

By Smollich Martin   Götte Martin   Fischgräbe Jeanett   Macedo Luciana   Brodie Angela   Chen Shiuan   Radke Isabel   Kiesel Ludwig   Wülfing Pia  

Breast Cancer Research and Treatment, Vol. 123, Iss. 2, 2010-09 ,pp. : 345-357

Springer Publishing Company

Access to resources Recommend Favorite

Aromatase Inhibitors: Indications for Breast Cancer Therapy

By Assikis V.J.  

American Journal of Cancer, Vol. 1, Iss. 2, 2002-02 ,pp. : 93-100

Adis International

Access to resources Recommend Favorite

Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracyclinebased neoadjuvant chemotherapy

By              

Molecular Medicine Reports, Vol. 9, Iss. 2, 2014-01 ,pp. : 614-620

Spandidos Publications

Access to resources Recommend Favorite

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective

By Dixon J.M.   Anderson T.J.   Miller W.R.  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2214-2221

Elsevier

Access to resources Recommend Favorite